Can Early Tirzepatid Use Change the Course of Type 2 Diabetes?

Exciting new findings in the field of Type 2 diabetes treatment were shared at the annual conference of the Amerikan Diyabet Derneği'nin (ADA).

The two-year results from the clinical trial named SUPPRESS-EARLY show that much higher success rates are achieved when drugs containing the active ingredient tirzepatid (Mounjaro ve Zepbound) are started in…